Table 1

Characteristics of the 40 patients who developed rituximab-related neutropenia

Sex37 F/3 M
Age54.3±19 years
DiagnosisRA: 25
SLE: 7
Vasculitis: 7
Myositis: 1
Disease duration9.2±7.5 years
CorticosteroidsYes: 27 (67.5%)
Mean dose of corticosteroidsRA: 6.3±7.2 mg/day
AIDs: 14.0±17.2 mg/day
Concomitant immunosuppressant other than corticosteroidsAbsent: 21 patients
Present: 19 patients

  • Methotrexate: 7

  • Leflunomide: 4

  • Hydroxychloroquine: 2

  • Cyclophosphamide:1

  • Methotrexate+hydroxychloroquine: 2

  • Mycophénolate mofétil: 1

  • Hydroxychloroquine+azathioprine: 1

  • Hydroxychloroquine+cyclophosphamide: 1

Regimen of rituximab1 g×2: 32 (80%)
375 mg/m2:8 (20%)

  • AIDs, autoimmune diseases; F, female; M, male; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.